TIAZAC Drug Patent Profile

When do Tiazac patents expire, and what generic alternatives are available?

Tiazac is a drug marketed by Bausch and is included in one NDA.

The generic ingredient in TIAZAC is diltiazem hydrochloride. There are twenty-six drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the diltiazem hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tiazac

A generic version of TIAZAC was approved as diltiazem hydrochloride by TEVA on May 31^st, 1995.

Summary for TIAZAC

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	2
Patent Applications:	3,360
Drug Prices:	Drug price information for TIAZAC
What excipients (inactive ingredients) are in TIAZAC?	TIAZAC excipients list
DailyMed Link:	TIAZAC at DailyMed

See drug prices for TIAZAC

Recent Clinical Trials for TIAZAC

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Assiut University	Early Phase 1
Bayer	Phase 3

See all TIAZAC clinical trials

Pharmacology for TIAZAC

Drug Class	Calcium Channel Blocker
Mechanism of Action	Calcium Channel Antagonists Cytochrome P450 3A4 Inhibitors

US Patents and Regulatory Information for TIAZAC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	TIAZAC	diltiazem hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020401-001	Sep 11, 1995	AB4	RX	Yes	No
Bausch	TIAZAC	diltiazem hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020401-004	Sep 11, 1995	AB4	RX	Yes	No
Bausch	TIAZAC	diltiazem hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020401-002	Sep 11, 1995	AB4	RX	Yes	No

Expired US Patents for TIAZAC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	TIAZAC	diltiazem hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020401-006	Oct 16, 1998	6,162,463
Bausch	TIAZAC	diltiazem hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020401-001	Sep 11, 1995	5,529,791
Bausch	TIAZAC	diltiazem hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020401-005	Sep 11, 1995	6,162,463

International Patents for TIAZAC

See the table below for patents covering TIAZAC around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0591424	DILTIAZEM SE PRESENTANT SOUS UNE FORME A LIBERATION PROLONGEE (EXTENDED-RELEASE FORM OF DILTIAZEM)
Austria	184196
World Intellectual Property Organization (WIPO)	9300093

Market Dynamics and Financial Trajectory for TIAZAC

Last updated: March 10, 2026

What is TIAZAC?

TIAZAC (chirally pure diltiazem) is a calcium channel blocker used primarily to treat hypertension and angina. Originally marketed as Dilacor XR, Tiazac has retained relevance through its formulation, offering extended release benefits.

Current Market Position

Tiazac is a branded formulation of diltiazem, which competes against generic versions and other calcium channel blockers like amlodipine and verapamil. Its market share remains relatively stable owing to its clinical profile and physician preferences, although off-patent status has driven generic proliferation.

Patent Status and Regulatory Landscape

• The original patent for Tiazac expired globally between 2010–2014.
• Generic versions became available from 2014 onward.
• No recent patents are active; any proprietary rights now are limited to formulation-specific advantages or marketing exclusivities.

Market Size and Revenue Estimates

• The global antihypertensive drugs market was valued at approximately USD 25 billion in 2021.
• Calcium channel blockers (including Tiazac) account for roughly 15% of this market segment USD 3.75 billion.
• Tiazac’s specific market revenue is estimated at USD 200–300 million annually, primarily sustained through branded sales in key markets like the U.S. and select European countries [1].

Competitive Environment

• Generic diltiazem extended-release formulations dominate sales, reducing Tiazac’s market share.
• Amlodipine and other newer agents have gained presence due to improved compliance and safety profiles.
• Brand loyalty and prescriber familiarity sustain Tiazac’s niche, especially among specific patient cohorts.

Pricing Trends and Revenue Impact

• Average retail price for Tiazac remains higher than generics, typically USD 10–15 per month’s supply versus USD 2–5 for generics.
• The introduction of generics in 2014 led to price erosion, with branded Tiazac prices decreasing significantly.
• Market access and reimbursement policies influence sales, with payers favoring generics for cost savings.

Market Drivers and Challenges

Drivers:

• Chronic hypertension prevalence: Estimated at over 1 billion worldwide.
• Aging populations: Increase in prescriptions for calcium channel blockers.
• Prescriber preference: Sustained for specific formulations like Tiazac in controlled-release cohorts.

Challenges:

• Patent expiration: Accelerates generic competition.
• Price erosion: Continues to suppress revenue.
• Regulatory hurdles: Limited barriers now as patents lapse.

Financial Trajectory Outlook

• Short-term: Revenue declines expected due to generic competition, with a projected 10–15% annual decrease over the next 3-5 years.
• Medium to long-term: Stabilization at lower revenue levels, potential for niche market revival through new formulations or combination therapies.
• Opportunities: Licensing, co-marketing partnerships, or formulation enhancements could generate supplemental revenue streams.

Geographical Variations

Region	Market Share	Key Factors	Revenue Estimates (USD million)
U.S.	High	Large hypertensive population, brand loyalty	150–200
Europe	Moderate	Generics prevalent, prescriber shifting	50–80
Asia	Growing	Increasing hypertension awareness	30–50

Strategic Recommendations

• Focus on differentiating formulations (e.g., extended-release advantages).
• Explore partnership opportunities for portfolio expansion.
• Invest in targeted marketing within niche segments where loyalty persists.
• Monitor regulatory shifts and patent landscapes to anticipate pipeline opportunities or risks.

Key Takeaways

• Tiazac holds a niche market position with stable but declining revenue primarily due to generic competition.
• Pricing dynamics favor generics, exerting downward pressure on brand sales.
• The market is driven by global hypertension prevalence, with regional variations influencing revenue.
• The short-term outlook suggests continued revenue erosion; long-term stability may depend on product differentiation or strategic licensing.
• Opportunities exist in formulation innovation and partnership models to extend product life cycle.

FAQs

1. What factors influence Tiazac's market share today?
Market share primarily depends on generic availability, pricing, prescriber preferences, and formulary inclusion.

2. How has patent expiry affected Tiazac's revenues?
Patent expiry in 2014 led to a surge in generic competition, significantly reducing branded sales revenue.

3. Are there new formulations of Tiazac under development?
No publicly announced new formulations are in advanced development stages; focus remains on existing formulations.

4. How does regional regulatory policy impact Tiazac’s sales?
Regions with strict approval pathways for generics and price controls tend to reduce branded drug sales more rapidly.

5. What growth opportunities exist for Tiazac in the future?
Market niche targeting, formulation improvements, or licensing deals could create additional revenue streams.

References

[1] IMS Health. (2022). Global antihypertensive market analysis.